Ming-Kuei Jang

Ming-Kuei Jang is the founder and CEO of APRINOIA Therapeutics. Ming-Kuei was previously the Institute Associate Director at MD Anderson Cancer Center, where they oversaw drug discovery and development for neurodegenerative diseases like Alzheimer's. Prior to that, they worked as a business development lead and senior research biologist at GlaxoSmithKline and Merck & Co respectively, both in the field of pre-clinical Alzheimer's research. Ming-Kuei has dedicated their career to finding a cure for Alzheimer's and other neurodegenerative diseases, and they are one of the leading experts in the field.

Ming-Kuei Jang did their postdoctoral training in neuroscience at Columbia University Vagelos College of Physicians and Surgeons. Then they did postdoctoral training in physiology at Northwestern University - The Feinberg School of Medicine. After that, they got their Ph.D. in pharmacology/neuroscience from Boston University School of Medicine. Ming-Kuei started their educational career with a B.S. in chemistry from National Taiwan University.

Some direct reports include Lili Zhang - SVP, Head of Preclinical Development, Bradford A. Navia - Chief Medical Officer, and Sanjay Sehgal - SVP & Global Head, Regulatory Affairs.